-800x600.JPG "Gemini acs ROYAL NETHERLANDS AIR FORCE Lockheed C-130H-30 1/400 NO.GMNAF021")
Gemini acs ROYAL NETHERLANDS AIR FORCE Lockheed C-130H-30 1/400 NO.GMNAF021
Objectives, The Site, Finance, and Role of The Ethics Committee, Sponsor and Research Organization
Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe | tctmd.com
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/5-Figure2-1.png "PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.")
PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS | tctmd.com
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/2-TableI-1.png "PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.")
PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology
GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC
Objectives, The Site, Finance, and Role of The Ethics Committee, Sponsor and Research Organization
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/3-TableII-1.png "PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.")
PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
The role of oral anticoagulant therapy in patients with acute coronary syndrome
Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges - ScienceDirect
Sanne van W💉ssen on Twitter: "Gemini-ACS1 results. Rivaroxaban shows same rate of clinically relevant bleeding compared to aspirin #ACS #ACC17 https://t.co/hZZHSHkVAB" / Twitter
Antithrombotic Therapy in Acute Coronary Syndrome: Striking a Happy Medium | Revista Española de Cardiología
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC
Syndrome coronaire aigu : l'étude GEMINI-ACS-1
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
Self-Assembly and Chiral Recognition of Chiral Cationic Gemini Surfactants | Langmuir
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome | SpringerLink
C. Michael Gibson MD on Twitter: "Download the full slide set of the GEMINI- ACS-1 trial presented at #ACC17 here https://t.co/euNbOEHThr https://t.co/1R99ZkA1md" / Twitter
Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis - Xie - 2021 - Clinical Cardiology - Wiley Online Library
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus. - ppt download
